🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,196 results for “GE” Clear

  1. Adagrasib

    Partner Therapeutics Limited

    Patients with KRASG12C-mutant NSCLC, including patients aged ≥18 years with poor performance status (ECOG PS=2) Cohort 1 or elderly (≥70 years) (ECOG PS=0-1) Cohort 2

    phase 2 small molecule active

    1 trial

  2. AdaptNK –Cell Therapy for High-risk Myeloid Disease

    The George Institute

    Relapsed and/or refractory AML or MDS

    phase 2 other active

    1 trial

  3. Adebrelimab+Albumin paclitaxel +Cisplatin

    The First People's Hospital of Lianyungang

    Locally Advanced Hypopharyngeal Cancer

    phase 2 small molecule active

    1 trial

  4. Adtralza 150 mg solution for injection in pre-filled syringe

    LEO Pharma A/S

    Treatment of moderate-to-severe Atopic dermatitis

    phase 2 small molecule active

    1 trial

  5. Adult Allogeneic Mesenchymal cells from adipose tissue.

    Lxo Ireland Designated Activity Company

    Acute Graft Versus Host Disease

    phase 2 small molecule completed

    1 trial

  6. Advagraf 0.5 mg prolonged-release hard capsules, Advagraf 1 mg prolonged-release hard capsules, Advagraf 1 mg prolonged-release hard capsules, Advagraf 5 mg prolonged-release hard capsules, Advagraf 1 mg prolonged-release hard capsules, Advagraf 0.5 mg prolonged-release hard capsules, Advagraf 0.5 mg prolonged-release hard capsules, Advagraf 1 mg prolonged-release hard capsules, Advagraf 0.5 mg prolonged-release hard capsules, Advagraf 1 mg prolonged-release hard capsules, Advagraf 0.5 mg prolonged-release

    Astellas Pharma GmbH

    Prophylaxis of primary liver, kidney, heart, lung, and intestinal organ transplant rejection

    phase 2 small molecule active

    1 trial

  7. Afatinib and Paclitaxel

    United Therapeutics Europe Ltd

    Esophageal Cancer

    phase 2 small molecule completed

    1 trial

  8. Afatinib once daily (OD)

    Boehringer Ingelheim

    Breast Neoplasms

    phase 2 small molecule completed

    1 trial

  9. Aflibercept

    Regeneron UK Limited

    Proliferative Diabetic Retinopathy

    phase 2 small molecule completed

    1 trial

  10. Aflibercept

    Regeneron UK Limited

    Radiation Retinopathy

    phase 2 small molecule active

    1 trial

  11. Aflibercept

    Regeneron UK Limited

    Advanced Carcinoma

    phase 2 small molecule terminated

    1 trial

  12. Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)

    Regeneron UK Limited

    Pulmonary Diseases

    phase 2 small molecule completed

    1 trial

  13. Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)

    Regeneron UK Limited

    Neoplasms

    phase 2 small molecule completed

    1 trial

  14. Aglatimagene besadenovec

    Candel Therapeutics

    Borderline Resectable Pancreatic Adenocarcinoma

    phase 2 mab active

    1 trial

  15. Aglatimagene besadenovec

    Candel Therapeutics

    Non Small Cell Lung Cancer

    phase 2 mab active

    1 trial

  16. Air médical en bouteille, OXYGEN

    Pari Pharma GmbH

    Alternating Hemiplegia of Childhood

    phase 2 small molecule active

    1 trial

  17. Aleniglipron or Placebo

    Structure Therapeutics

    Obesity, Overweight, or Chronic Weight Management

    phase 2 small molecule active

    2 trials

  18. Alirocumab

    Regeneron UK Limited

    Non Small Cell Lung Cancer

    phase 2 small molecule on hold

    1 trial

  19. Alirocumab

    Regeneron UK Limited

    Nephrotic Syndrome

    phase 2 small molecule terminated

    1 trial

  20. Alirocumab and Cemiplimab

    Regeneron UK Limited

    Non-small Cell Lung Cancer (NSCLC)

    phase 2 other active

    1 trial

  21. Alisertib

    Takeda

    Diffuse Large B-cell Lymphoma

    phase 2 small molecule completed

    1 trial

  22. Alisertib

    Takeda

    Acute Myelogenous Leukemia

    phase 2 small molecule completed

    1 trial

  23. Alisertib (MLN8237)

    Takeda

    Diffuse Large B-Cell Lymphoma

    phase 2 small molecule completed

    1 trial

  24. Alkotinib Capsules

    Suzhou Zelgen Biopharmaceuticals Co.,Ltd

    ALK-positive Non-small Cell Lung Cancer

    phase 2 small molecule terminated

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources